TREATMENT PATTERNS AMONG LOWER-INCOME INDIAN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATIONS OR ALK REARRANGEMENTS

被引：2
|
作者：
Vashistha, Vishal
Garg, Avneet
Iyer, Hariharan
Jain, Deepali
Madan, Karan
Guleria, Randeep
Mohan, Anant
机构：
来源：
CHEST | 2020年 / 158卷 / 04期
关键词：
D O I：
10.1016/j.chest.2020.08.1621
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：1869A / 1869A
页数：1
相关论文
共 50 条
  • [31] ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non-small cell lung cancer
    Hou, Helei
    Sun, Dantong
    Zhang, Chuantao
    Liu, Dong
    Zhang, Xiaochun
    THORACIC CANCER, 2021, 12 (06) : 962 - 969
  • [32] ALK Rearrangement and EGFR Copy Number Gains/mutations in Czech Non-small Cell Lung Cancer Patients
    Koudelakova, V.
    Trojanec, R.
    Kneblova, M.
    Drabek, J.
    Kolar, Z.
    Kolek, V.
    Mlcochova, S.
    Hajduch, M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S139 - S139
  • [33] Beyond EGFR and ALK: targeting rare mutations in advanced non-small cell lung cancer
    Gkolfinopoulos, Stavros
    Mountzios, Giannis
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (08)
  • [34] THE ECONOMIC BURDEN OF METASTATIC NON-SMALL CELL LUNG CANCER IN US PATIENTS WITHOUT AN EGFR OR ALK MUTATION
    Simmons, D.
    Welch, E.
    Pyrih, N.
    Jiang, Z.
    Xiao, Y.
    Jassim, R.
    VALUE IN HEALTH, 2023, 26 (06) : S108 - S108
  • [35] Cytological samples for the study of EGFR, KRAS and ALK mutations in non-small cell lung cancer
    Becker, Caroline
    Carcereny Costa, Enric
    Andreo Garcia, Felipe
    Castella, Eva
    Lletjos Sanuy, Mariona
    Moran, Teresa
    Mijangos Basterra, Erika
    Sanz Santos, Jose
    Centeno Clemente, Carmen
    Ruiz Manzano, Juan
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [36] Correction to: EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non‑Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
    Xiuning Le
    Eric Nadler
    Daniel B. Costa
    John Victor Heymach
    Targeted Oncology, 2024, 19 : 125 - 125
  • [37] Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors
    Heigener, David F.
    Schumann, Christian
    Sebastian, Martin
    Sadjadian, Parvis
    Stehle, Ingo
    Maerten, Angela
    Lueers, Anne
    Griesinger, Frank
    Scheffler, Matthias
    ONCOLOGIST, 2015, 20 (10): : 1167 - 1174
  • [38] CUSTOMIZING ERLOTINIB IN METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (P) HARBORING EGFR MUTATIONS
    Sirera, R.
    Catot, S.
    Gonzalez-Larriba, J. L.
    Bover, I.
    Alonso, G.
    Valdivia, J.
    Ibeas, R.
    Lianes, P.
    Martinez del Prado, P.
    Rosell, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 90 - 90
  • [39] ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer
    Guerin, Annie
    Sasane, Medha
    Zhang, Jie
    Macalalad, Alexander R.
    Galebach, Philip
    Jarvis, John
    Kageleiry, Andrew
    Culver, Kenneth
    Wu, Eric Q.
    Wakelee, Heather
    CANCER EPIDEMIOLOGY, 2015, 39 (03) : 307 - 312
  • [40] EGFR mutations and gefitinib sensitivity in patients with metastatic non-squamous non-small cell lung cancer
    Moiseyenko, V.
    Imyanitov, E.
    Levchenko, E.
    Procenko, S.
    Orlova, R.
    Iyevleva, A.
    Buslov, K.
    Ulibina, Y.
    Matsko, D.
    Moiseyenko, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345